Comparative profiling of the novel epothilone, sagopilone, in xenografts derived from primary non-small cell lung cancer

Clinical Cancer Research

Volumn 16, Issue 5, 2010, Pages 1452-1465

  Hammer, Stefanie ^a   Sommer, Anette ^a   Fichtner, Iduna ^b,c   Becker, Michael ^c   Rolff, Jana ^c   Merk, Johannes ^d   Klar, Ulrich ^a   Hoffmann, Jens ^a,b,c  

^a BAYER PHARMA AG   (Germany)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^c Experimental Pharmacology and Oncology GmbH   (Germany)

^d Evangelische Lungenklinik Berlin   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; ETOPOSIDE; GEMCITABINE; NAVELBINE; PACLITAXEL; PROTEIN P53; SAGOPILONE; SORAFENIB; TUBULIN; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CELL ADHESION; CONTROLLED STUDY; DRUG EFFICACY; DRUG TARGETING; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENOME; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MITOSIS INHIBITION; MOUSE; MULTIPLE CYCLE TREATMENT; MUTATIONAL ANALYSIS; NONHUMAN; PATIENT IDENTIFICATION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TUMOR XENOGRAFT; WILD TYPE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; BENZOTHIAZOLES; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE, NEOPLASM; EPOTHILONES; GENE EXPRESSION PROFILING; HUMANS; LUNG NEOPLASMS; MICE; PYRIDINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77649122679     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-2455     Document Type: Article

References (56)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Argiris A, Schiller JH. Can current treatments for advanced non-small-cell lung cancer be improved? JAMA 2004;292:499-500.
3. Carney DN, Hansen HH. Non-small-cell lung cancer - stalemate or progress? N Engl J Med 2000;343:1261-2.
4. Ramalingam S, Belani C. Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions. Oncologist 2008;13:5-13.
5. Georgoulias V, Papadakis E, Alexopoulos A, et al. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial. Lancet 2001;357: 1478-84.
6. Kosmidis PA, Kalofonos HP, Christodoulou C, et al. Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group. Ann Oncol 2008;19:115-22.
7. Haddad TC, Yee D. Of mice and (wo)men: Is this any way to test a new drug? J Clin Oncol 2008;26:830-2.
8. Sharpless NE, Depinho RA. The mighty mouse: genetically engineered mouse models in cancer drug development. Nat Rev Drug Discov 2006;5:741-54.
9. Furman WL, Stewart CF, Poquette CA, et al. Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children. J Clin Oncol 1999;17:1815-24.
10. Angevin E, Glukhova L, Pavon C, et al. Human renal cell carcinoma xenografts in SCID mice: tumorigenicity correlates with a poor clinical prognosis. Lab Invest 1999;79:879-88.
11. Peterson JK, Houghton PJ. Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development. Eur J Cancer 2004;40:837-44.
12. Garber K. From human to mouse and back: "tumorgraft" models surge in popularity. J Natl Cancer Inst 2009;101:6-8.
13. Becker M, Sommer A, Kratzschmar JR, Seidel H, Pohlenz HD, Fichtner I. Distinct gene expression patterns in a tamoxifen-sensitive human mammary carcinoma xenograft and its tamoxifen-resistant subline MaCa 3366/TAM. Mol Cancer Ther 2005;4: 151-68.
14. Fichtner I, Becker M, Zeisig R, Sommer A. In vivo models for endocrine-dependent breast carcinomas: special considerations of clinical relevance. Eur J Cancer 2004;40:845-51.
15. Fichtner I, Rolff J, Soong R, et al. Establishment of patient-derived non small cell lung cancer (NSCLC) xenografts as models for the identification of predictive biomarkers. Clin Cancer Res 2008;14:6456-68.
16. Perez-Soler R, Kemp B, Wu QP, et al. Response and determinants of sensitivity to paclitaxel in human non-small cell lung cancer tumors heterotransplanted in nude mice. Clin Cancer Res 2000;6: 4932-8.
17. Nevins JR, Huang ES, Dressman H, Pittman J, Huang AT, West M. Towards integrated clinico-genomic models for personalized medicine: combining gene expression signatures and clinical factors in breast cancer outcomes prediction. Hum Mol Genet 2003;12: R153-7.
18. Teicher BA. Newer cytotoxic agents: attacking cancer broadly. Clin Cancer Res 2008;14:1610-7.
19. Bollag DM, McQueney PA, Zhu J, et al. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res 1995;55:2325-33.
20. Kowalski RJ, Giannakakou P, Hamel E. Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol r). J Biol Chem 1997; 272:2534-41.
21. Lee FYF, Borzilleri R, Fairchild CR, et al. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res 2001;7: 1429-37.
22. Hoffmann J, Vitale I, Buchmann B, et al. Improved cellular pharmacokinetics and pharmacodynamics underlie the wide anticancer activity of sagopilone. Cancer Res 2008;68:5301-8.
23. Klar U, Buchmann B, Schwede W, Skuballa W, Hoffmann J, Lichtner RB. Total synthesis and anti-tumor activity of ZK-EPO: the first fully synthetic epothilone in clinical development. Angew Chem Int Ed Engl 2006;45:7942-8.
24. Galmarini CM. Sagopilone, a microtubule stabilizer for the potential treatment of cancer. Curr Opin Investig Drugs 2009;10:1359-71.
25. Gatzemeier U, von Pawel J, Eschbach C, et al. Phase II trial of the novel epothilone sagopilone (ZK-EPO) as second-line therapy in patients with stage IIIB or stage IV non-small-cell lung cancer. ECCO 14, Barcelona, Spain. 2007, p. 6568.
26. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
27. Braakhuis BJ, Ruiz van Haperen VW, Boven E, Veerman G, Peters GJ. Schedule-dependent antitumor effect of gemcitabine in in vivo model system. Semin Oncol 1995;22:42-6.
28. Brantley-Sieders DM, Chen J. Eph receptor tyrosine kinases in angiogenesis:from development to disease. Angiogenesis 2004; 7:17-28.
29. Cheng N, Brantley DM, Chen J. The ephrins and Eph receptors in angiogenesis. Cytokine Growth Factor Rev 2002;13:75-85.
30. Beyer S, Kristensen MM, Jensen KS, Johansen JV, Staller P. The histone demethylases JMJD1A and JMJD2B are transcriptional targets of hypoxia-inducible factor HIF. J Biol Chem 2008;283: 36542-52.
31. Brahimi-Horn MC, Chiche J, Pouyssegur J. Hypoxia and cancer. J Mol Med 2007;85:1301-7.
32. Mitsios N, Saka M, Krupinski J, et al. A microarray study of gene and protein regulation in human and rat brain following middle cerebral artery occlusion. BMC Neurosci 2007;8:93.
33. Nikolopoulos SN, Blaikie P, Yoshioka T, Guo W, Giancotti FG. Integrin β4 signaling promotes tumor angiogenesis. Cancer Cell 2004;6: 471-83.
34. Somanath PR, Ciocea A, Byzova TV. Integrin and growth factor receptor alliance in angiogenesis. Cell Biochem Biophys 2009;53: 53-64.
35. Daniel VC, Marchionni L, Hierman JS, et al. A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. Cancer Res 2009;69:3364-73.
36. Nettles JH, Li H, Cornett B, Krahn JM, Snyder JP, Downing KH. The binding mode of epothilone A on α,β-tubulin by electron crystallography. Science 2004;305:866-9.
37. Nogales E, Wolf SG, Khan IA, Luduena RF, Downing KH. Structure of tubulin at 6.5 A and location of the taxol-binding site. Nature 1995; 375:424-7.
38. Bracker TU, Sommer A, Fichtner I, Faus H, Haendler B, Hess-Stumpp H. Efficacy of MS-275, a selective inhibitor of class I histone deacetylases, in human colon cancer models. Int J Oncol 2009;35:909-20.
39. Mozzetti S, Iantomasi R, De Maria I, et al. Molecular mechanisms of patupilone resistance. Cancer Res 2008;68:10197-204.
40. Burkhart CA, Kavallaris M, Band HS. The role of β-tubulin isotypes in resistance to antimitotic drugs. Biochim Biophys Acta 2001;1471:1-9.
41. Ferlini C, Raspaglio G, Cicchillitti L, et al. Looking at drug resistance mechanisms for microtubule interacting drugs: Does TUBB3 work? Curr Cancer Drug Targets 2007;7:704-12.
42. Kavallaris M, Kuo DY, Burkhart CA, et al. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific β-tubulin isotypes. J Clin Invest 1997;100:1282-93.
43. Liu B, Staren ED, Iwamura T, Appert HE, Howard JM. Mechanisms of taxotere-related drug resistance in pancreatic carcinoma. J Surg Res 2001;99:179-86.
44. Ranganathan S, Benetatos CA, Colarusso PJ, Dexter DW, Hudes GR. Altered β-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells. Br J Cancer 1998;77:562-6.
45. Seve P, Isaac S, Tredan O, et al. Expression of class III {β}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy. Clin Cancer Res 2005;11:5481-6.
46. Sekine I, Minna JD, Nishio K, Tamura T, Saijo N. A literature review of molecular markers predictive of clinical response to cytotoxic chemotherapy in patients with lung cancer. J Thorac Oncol 2006;1:31-7.
47. Cosse JP, Michiels C. Tumour hypoxia affects the responsiveness of cancer cells to chemotherapy and promotes cancer progression. Anticancer Agents Med Chem 2008;8:790-7.
48. Ivanov S, Liao SY, Ivanova A, et al. Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am J Pathol 2001;158:905-19.
49. Araujo A, Ribeiro R, Azevedo I, et al. Genetic polymorphisms of the epidermal growth factor and related receptor in non-small cell lung cancer-a review of the literature. Oncologist 2007;12:201-10.
50. Aviel-Ronen S, Blackhall FH, Shepherd FA, Tsao MS. K-ras mutations in non-small-cell lung carcinoma: a review. Clin Lung Cancer 2006;8:30-8.
51. Sato M, Shames DS, Gazdar AF, Minna JD. A translational view of the molecular pathogenesis of lung cancer. J Thorac Oncol 2007;2: 327-43.
52. Mitsudomi T, Hamajima N, Ogawa M, Takahashi T. Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis. Clin Cancer Res 2000;6:4055-63.
53. O'Connor PM, Jackman J, Bae I, et al. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growthinhibitory potency of 123 anticancer agents. Cancer Res 1997;57: 4285-300.
54. Kawasaki M, Nakanishi Y, Kuwano K, Takayama K, Kiyohara C, Hara N. Immunohistochemically detected p53 and P-glycoprotein predict the response to chemotherapy in lung cancer. Eur J Cancer 1998;34: 1352-7.
55. Fischer J, von Pawel J, Schmittel A, et al. Phase II trial of the novel epothilone sagopilone (ZK-EPO), a novel epothilone, as second-line therapy in patients with stage IIIB-IV non-small-cell lung cancer. Stockholm (Sweden): ESMO 33; 2008, p. 301P.
56. Schmid P, Kiewe P, Possinger K, et al. Phase I study of the novel, fully synthetic epothilone sagopilone (ZK-EPO) in patients with solid tumors. Ann Oncol 2009 Oct 30 (Epub ahead of print).